The first EMS agency to purchase the E Series is Peoria, Ill.-based Advanced Medical Transport (AMT), which operates the largest ambulance fleet in Central Illinois. According to AMT’s Executive Director, Andrew Rand, “The innovative design and feature set of the E Series make it apparent that ZOLL has listened to professional rescuers and built a top-notch defibrillator designed exclusively for the world of EMS. We purchased the E Series because of ZOLL’s clear understanding of what it takes to develop the best life-saving tools for caregivers and their patients.”
The E Series is the only defibrillator available today that:
• Features a suitcase-style design with an innovative, protective roll cage, allowing EMS customers to carry or store the device more easily;
• Exceeds all other defibrillators in terms of overall ruggedness and durability;
• Provides an EasyRead Tri-Mode Display™ for use in pitch dark or direct sunlight, providing superior readability and complete views of critical patient information from virtually any angle;
• Is equipped with a built-in GPS clock, allowing customers to automatically synchronize all of their dispatch, defibrillator, and intervention call times, improving overall data accuracy;
• Offers a Rapid Cable Deployment System™ that helps manage all the parameter cables, allowing for faster deployment and avoiding the “spaghetti in the bag” that can be associated with other defibrillators;
• Is compatible with ZOLL’s sealed lead acid 4410 Smart Battery™ as well rechargeable lithium ion, allowing the E Series to function with new and existing battery technologies; and
• Integrates optional Bluetooth® functionality to provide data transmission capability to a variety of destinations.
In addition, the E Series is RescueNet™ Ready and can easily transfer patient and clinical data to ZOLL’s range of RescueNet Field Data collection options. RescueNet is the only suite of fully integrated EMS software applications that combines patient and medical device information, and streamlines operations by managing data from the emergency call to patient billing.
The E Series uses ZOLL’s proprietary Rectilinear Biphasic™ Waveform (RBW). The ZOLL RBW is the only biphasic waveform cleared by the FDA to claim superiority to monophasic waveforms for the conversion of ventricular fibrillation in high impedance patients. ZOLL is the only company to receive this FDA clearance to make such superiority claims since the development of defibrillation in the 1950s. Only the ZOLL RBW has demonstrated statistical clinical superiority to monophasic waveforms in peer-reviewed controlled trials, with data from more than 11,500 patients.
“The E Series builds on the success of the well-established M Series™ line of defibrillators, while offering a number of industry firsts in the areas of design, usability, documentation, and data management,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “We are encouraged by the positive early reaction to the product from the EMS marketplace.”
Mr. Packer continued, “While we expect that this introduction will help us continue to gain traction in the EMS marketplace, revenue from the E Series will ramp up over time and will have a moderate effect on the fourth quarter. In addition, we expect sales of the E Series to help drive adoption of other products, such as the ZOLL AutoPulse,™ as more customers understand how ZOLL’s products work together to advance the practice of resuscitation, and help rescuers save lives that would otherwise be lost.”
About ZOLL Medical Corporation
ZOLL Medical Corporation (NASDAQ: ZOLL) is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation, ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that can help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical data.
ZOLL has operations in the United States, Canada, the United Kingdom, Germany, France, The Netherlands, Australia, and Austria. With direct operations, international offices, and business partners in all of the world’s major markets, ZOLL markets and sells its products in more than 140 countries.
Certain statements contained in this press release, including statements regarding the anticipated development of the Company’s business, expectations concerning future product revenues and financial results and other statements contained in this press release regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company’s Quarterly Report on Form 10Q filed with the SEC on May 13, 2005, including the future performance of the direct sales operations, as well as uncertainties regarding the market acceptance and profitability of the Company’s products.